CytoMed Therapeutics Limited (GDTC )

Currency in USD Disclaimer
$1.08 +$0.23 (27.07%)
Closed 02/05/2026
$0.9
$1.25
$0.73
$3.68

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

  • Symbol GDTC
  • Company CytoMed Therapeutics Limited
  • Price $1.08
  • Changes Percentage 27.07
  • Change 0.23
  • Day Low $0.9
  • Day High $1.25
  • Year High $3.68
  • Year Low $0.73
  • Market Cap $12,672,409
  • Price Avg 50 EMA (D) $1.36
  • Price Avg 200 EMA (D) $1.91
  • Exchange NASDAQ
  • Volume 21,816,974
  • Average Volume 573,544
  • Open $1.05
  • Previous Close $0.85
  • EPS -0.25
  • PE -4.32
  • Earnings Announcement 2026-05-04 12:00:00
  • Shares Outstanding $11,733,712

Company brief: CYTOMED THERAPEUTICS LIMITED (GDTC )

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers. The company's lead product candidate is CTM-N2D, which consists of expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, which utilizes iPSC as a starting material to generate gdNKT, a synthetic hybrid of a gamma delta T cell and a NK cell; and CTM-GDT, a product candidate that consists of expanded gamma delta T cells, and exploits the multiple recognition system of gamma delta T cell to recognize and treat a range of cancers. The company was incorporated in 2018 and is headquartered in Singapore.

GDTC Corporation News

Income Statement